PM.20.037 – Personalized nuclear interventions by proven knowledge
Curing cancer is one of the main challenges in Western healthcare. With over 3.5 million new cases each year, cancer represents the second most important cause of morbidity and death in Europe. Although there are many new developments in cancer management, improvements in patient survival are limited. Therefore, investments in personalized medicine to increase patient survival are essential. Nuclear medicine can play a major role here; not only by identifying the optimal therapy for each patient via non-invasive imaging of biological targets or pathways, but also by offering personalized radionuclide therapy via selection of the most optimal radionuclide improvement of radiation-dose to the tumor. Within this approach the individual patient will be placed central in nuclear treatment approach. Biological responses to different types of radiation can result in direct (cancer) cell killing or indirectly via induction of an anti-tumor immune response. Despite these potentials, there are impediments that limit the development of personalized nuclear medicine such as insufficient knowledge on the biological response to different radiation doses and the availability of medical radionuclides. Remarkably, despite the widespread use of therapeutic radionuclides, the fundamental mechanisms underlying the efficacy, distribution and response mechanism are still largely unknown. The used radionuclides in different therapies are often chosen because of availability, ease to label, history or theoretical principles. Outcome of project will enable personalized cancer treatment by fully understanding the radiobiological effects of radionuclide-based therapies and will increase the availability of medical radionuclides. The project is therefore expected to have great societal impact; it will strengthen the fundamental knowledge necessary to realize personalized treatment of patients and it will support the nuclear industry to be prepared for the future demand of medical isotopes.
Medical isotopes, Personalized medicine, Radiobiology, Targeted therapy
Erasmus Medical Center (EMC), Hubrecht Organoids Institute, Maastricht UMC (MUMC), Pallas, Quirem Medical, SCK CEN, Technische Universiteit Delft (TUD), UMC Utrecht (UMCU), Utrecht University (UU)
|Organisation||Radboudumc Nijmegen (RUMC)|
|Name||Dr. J.F.W. (Frank) Nijsen|